AZN:LON
AstraZeneca PLC (US)
GBX 11,680.00
arrow_downward
-1.65%(-196.00) 1D
Sep 9, 2:25:13 PM GMT+1 · GBX
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for AZN...
Open
GBX 11,850.00
High
GBX 11,998.00
Low
GBX 11,668.00
Mkt. cap
180.93B
Avg. vol.
3.65M
Volume
724.50K
Dividend
2.05%
Quarterly dividend
GBX 59.75
Ex-dividend date
Aug 6, 2026
P/E ratio
23.64
52-wk high
GBX 15,732.00
52-wk low
GBX 9,892.00
EPS
GBX 4.94
Shares outstanding
1.55B
No. of employees
96K
Open
GBX 11,850.00
High
GBX 11,998.00
Low
GBX 11,668.00
Mkt. cap
180.93B
Avg. vol.
3.65M
Volume
724.50K
Dividend
2.05%
Quarterly dividend
GBX 59.75
Ex-dividend date
Aug 6, 2026
P/E ratio
23.64
52-wk high
GBX 15,732.00
52-wk low
GBX 9,892.00
EPS
GBX 4.94
Shares outstanding
1.55B
No. of employees
96K
News stories
From web sources and news partners
Investing.com
·
4 hours ago
RBC Capital initiates AstraZeneca stock at Outperform, sets target at £145
AD HOC NEWS
·
7 hours ago
AstraZeneca stock edges lower ahead of the open after Imfinzi trial win
Kalkine Media
·
8 hours ago
AstraZeneca Stock: What’s Shaping Investor Attention?
Profile
AstraZeneca plc is a Swedish–British multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, England. It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation.
The company was founded in 1999 through the merger of the Swedish Astra AB and the British Zeneca Group. Zeneca shareholders received 53.5% of the shares, while Astra shareholders received the remaining 46.5%. Its portfolio includes primary and speciality care, coverage for rare diseases, and a robust global presence across various regions. Since the merger it has been among the world's largest pharmaceutical companies and has made numerous corporate acquisitions, including Cambridge Antibody Technology, MedImmune, Spirogen and Definiens. It has its research and development concentrated in three strategic centres: Cambridge, England; Gothenburg, Sweden; and Gaithersburg, Maryland, US.
AstraZeneca traces its earliest corporate history to 1913, when Astra AB was formed by a large group of doctors and apothecaries in Södertälje. Wikipedia
About AstraZeneca PLC (US)
CEOPascal Soriot
Employees96.1K
FoundedApr 6, 1999
HeadquartersCambridge, Cambridgeshire, United Kingdom
SectorPharmaceutical industry
Websiteastrazeneca.com